A predictive model for functional cure in chronic HBV patients treated with pegylated interferon alpha: a comparative study of multiple algorithms based on clinical data.

IF 4 3区 医学 Q2 VIROLOGY
Ya-Mei Ye, Yong Lin, Fang Sun, Wen-Yan Yang, Lina Zhou, Chun Lin, Chen Pan
{"title":"A predictive model for functional cure in chronic HBV patients treated with pegylated interferon alpha: a comparative study of multiple algorithms based on clinical data.","authors":"Ya-Mei Ye, Yong Lin, Fang Sun, Wen-Yan Yang, Lina Zhou, Chun Lin, Chen Pan","doi":"10.1186/s12985-024-02599-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>A multivariate predictive model was constructed using baseline and 12-week clinical data to evaluate the rate of clearance of hepatitis B surface antigen (HBsAg) at the 48-week mark in patients diagnosed with chronic hepatitis B who are receiving treatment with pegylated interferon α (PEG-INFα).</p><p><strong>Methods: </strong>The study cohort comprised CHB patients who received pegylated interferon treatment at Mengchao Hepatobiliary Hospital, Fujian Medical University, between January 2019 and April 2024. Predictor variables were identified (LASSO), followed by multivariate analysis and logistic regression analysis. Subsequently, predictive models were developed via logistic regression, random forest (RF), gradient boosting decision tree (GBDT), extreme gradient boosting (XGBoost), and support vector machine (SVM) algorithms. The efficacy of these models was assessed through various performance metrics, including the area under the receiver operating characteristic curve (AUC), sensitivity, specificity, and F1 score.</p><p><strong>Results: </strong>This study included a total of 224 individuals diagnosed with chronic hepatitis B. The variables baseline log<sub>2</sub>(HBsAg), gender, age, neutrophil count at week 12, HBsAg decline rate at week 12, and HBcAb at week 12 were closely associated with functional cure and were included in the predictive model. In the validation term, the logistic regression model had an AUC of 0.858, which was better than that of the other machine learning models (AUC = 0.858,F1 = 0.753). Consequently, this model was selected for the development of the predictive tool.</p><p><strong>Conclusions: </strong>The combined use of the baseline log<sub>2</sub>(HBsAg) value, HBsAg decline rate at week 12, gender, neutrophil count at week 12, and age can serve as a foundational predicting model for anticipating the clearance of HBsAg in individuals with chronic hepatitis B who are receiving PEG-INFα therapy.</p>","PeriodicalId":23616,"journal":{"name":"Virology Journal","volume":"21 1","pages":"333"},"PeriodicalIF":4.0000,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11665216/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Virology Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12985-024-02599-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"VIROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: A multivariate predictive model was constructed using baseline and 12-week clinical data to evaluate the rate of clearance of hepatitis B surface antigen (HBsAg) at the 48-week mark in patients diagnosed with chronic hepatitis B who are receiving treatment with pegylated interferon α (PEG-INFα).

Methods: The study cohort comprised CHB patients who received pegylated interferon treatment at Mengchao Hepatobiliary Hospital, Fujian Medical University, between January 2019 and April 2024. Predictor variables were identified (LASSO), followed by multivariate analysis and logistic regression analysis. Subsequently, predictive models were developed via logistic regression, random forest (RF), gradient boosting decision tree (GBDT), extreme gradient boosting (XGBoost), and support vector machine (SVM) algorithms. The efficacy of these models was assessed through various performance metrics, including the area under the receiver operating characteristic curve (AUC), sensitivity, specificity, and F1 score.

Results: This study included a total of 224 individuals diagnosed with chronic hepatitis B. The variables baseline log2(HBsAg), gender, age, neutrophil count at week 12, HBsAg decline rate at week 12, and HBcAb at week 12 were closely associated with functional cure and were included in the predictive model. In the validation term, the logistic regression model had an AUC of 0.858, which was better than that of the other machine learning models (AUC = 0.858,F1 = 0.753). Consequently, this model was selected for the development of the predictive tool.

Conclusions: The combined use of the baseline log2(HBsAg) value, HBsAg decline rate at week 12, gender, neutrophil count at week 12, and age can serve as a foundational predicting model for anticipating the clearance of HBsAg in individuals with chronic hepatitis B who are receiving PEG-INFα therapy.

聚乙二醇化干扰素治疗慢性HBV患者功能治愈的预测模型:基于临床数据的多种算法的比较研究
背景:使用基线和12周临床数据构建了一个多变量预测模型,以评估接受聚乙二醇化干扰素α (PEG-INFα)治疗的慢性乙型肝炎患者48周时乙型肝炎表面抗原(HBsAg)的清除率。方法:研究队列包括2019年1月至2024年4月在福建医科大学孟潮肝胆医院接受聚乙二醇化干扰素治疗的CHB患者。采用LASSO法确定预测变量,然后进行多因素分析和logistic回归分析。随后,通过逻辑回归、随机森林(RF)、梯度增强决策树(GBDT)、极端梯度增强(XGBoost)和支持向量机(SVM)算法建立预测模型。这些模型的疗效通过各种性能指标进行评估,包括受试者工作特征曲线下面积(AUC)、敏感性、特异性和F1评分。结果:该研究共纳入224例慢性乙型肝炎患者。基线log2(HBsAg)、性别、年龄、第12周中性粒细胞计数、第12周HBsAg下降率和第12周HBcAb等变量与功能性治愈密切相关,并被纳入预测模型。在验证期内,logistic回归模型的AUC为0.858,优于其他机器学习模型(AUC = 0.858,F1 = 0.753)。因此,该模型被选择用于预测工具的开发。结论:综合使用基线log2(HBsAg)值、第12周HBsAg下降率、性别、第12周中性粒细胞计数和年龄可以作为预测接受PEG-INFα治疗的慢性乙型肝炎患者HBsAg清除的基础预测模型。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Virology Journal
Virology Journal 医学-病毒学
CiteScore
7.40
自引率
2.10%
发文量
186
审稿时长
1 months
期刊介绍: Virology Journal is an open access, peer reviewed journal that considers articles on all aspects of virology, including research on the viruses of animals, plants and microbes. The journal welcomes basic research as well as pre-clinical and clinical studies of novel diagnostic tools, vaccines and anti-viral therapies. The Editorial policy of Virology Journal is to publish all research which is assessed by peer reviewers to be a coherent and sound addition to the scientific literature, and puts less emphasis on interest levels or perceived impact.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信